A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects With Wiskott-Aldrich Syndrome

Learn more about:
Related Clinical Trial
Romiplostim Treatment for Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome. Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome Bone Marrow Transplant With Abatacept for Non-Malignant Diseases Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Alpha/Beta T and CD19+ Depleted Peripheral Stem Cells for Patients With Primary Immunodeficiencies Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP) Participation in a Research Registry for Immune Disorders Haploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich Syndrome Gene Therapy for Wiskott-Aldrich Syndrome (WAS) Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome (WAS) Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990 A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects With Wiskott-Aldrich Syndrome Post-transplant Cyclophosphamide in Wiskott-Aldrich Syndrome Long Term Safety Follow up of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome Interleukin-2 Treatment for Wiskott-Aldrich Syndrome Gene Therapy for WAS Targeted Literature Review and Subject Interviews in Wiskott-Aldrich Syndrome (WAS) Molecular and Clinical Studies of Primary Immunodeficiency Diseases A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients

Brief Title

A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects With Wiskott-Aldrich Syndrome

Official Title

A Single Arm, Open-label Clinical Trial of Hematopoietic Stem Cell Gene Therapy With Cryopreserved Autologous CD34+ Cells Transduced With Lentiviral Vector Encoding WAS cDNA in Subjects With Wiskott-Aldrich Syndrome (WAS)

Brief Summary

      This is an open-label, single arm study to evaluate the cryopreserved formulation of OTL-103
      Gene Therapy. OTL-103 consists of autologous CD34+ hematopoietic stem cells in which the gene
      encoding for the Wiskott-Aldrich Syndrome is introduced by means of a third generation
      lentiviral vector.
    


Study Phase

Phase 3

Study Type

Interventional


Primary Outcome

Annualized rate of severe infections from 6 to 18 months after gene therapy compared with 1 year before gene therapy

Secondary Outcome

 Evaluation of the overall survival

Condition

Wiskott-Aldrich Syndrome

Intervention

OTL-103

Study Arms / Comparison Groups

 Gene Therapy
Description:  OTL-103, Autologous CD34+ hematopoietic stem cells transduced ex vivo with a lentiviral vector encoding the human WAS gene

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Genetic

Estimated Enrollment

6

Start Date

January 21, 2019

Completion Date

December 2022

Primary Completion Date

February 2022

Eligibility Criteria

        Inclusion Criteria:

          -  Age: up to 65 years

          -  Diagnosis of WAS defined by genetic mutation and at least one of the following
             criteria:

               -  Severe Wiskott-Aldrich Syndrome (WAS) gene mutation, defined by literature data
                  (genotype/phenotype studies).;

               -  Absent WASP expression, assessed by flow cytometry;

               -  Severe clinical score (Zhu clinical score ≥ 3);

          -  No human leukocyte antigen (HLA)-identical related donor available for hematopoietic
             stem cells transplant (HSCT).

        Exclusion Criteria:

          -  End-organ dysfunction, severe active infection not responsive to treatment or other
             severe disease or clinical condition which, in the judgment of the investigator, would
             make the patient inappropriate for entry into this study.

          -  Malignant neoplasia (except local skin cancer) or a documented history of hereditary
             cancer syndrome.

          -  Myelodysplasia, cytogenetic alterations characteristic of myelodysplastic syndrome and
             acute myeloid leukaemia , or other serious haematological disorders

          -  Documented human immunodeficiency virus (HIV) infection

          -  Prior allogeneic hematopoietic stem cell transplantation, with evidence of residual
             cells of donor origin

          -  Previous Gene Therapy
      

Gender

All

Ages

N/A - 65 Years

Accepts Healthy Volunteers

No

Contacts

Orchard Clinical Trials, , 

Location Countries

Italy

Location Countries

Italy

Administrative Informations


NCT ID

NCT03837483

Organization ID

OTL-103-4

Secondary IDs

2018-003842-18

Responsible Party

Sponsor

Study Sponsor

Orchard Therapeutics

Collaborators

 Ospedale San Raffaele

Study Sponsor

Orchard Clinical Trials, Study Director, Orchard Therapeutics (Europe) Limited


Verification Date

December 2020